Ketoglutaric acid can reprogram the immunophenotype of triple-negative breast cancer after radiotherapy and improve the therapeutic effect of anti-PD-L1

BACKGROUND: Great progress has been made in applying immunotherapy to the clinical treatment of tumors. However, many patients with triple-negative breast cancer (TNBC) cannot benefit from immunotherapy due to the immune desert type of TNBC, which is unresponsive to immunotherapy. DMKG, a cell-perme...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Hongpei, Liu, Jiahao, Huang, Jing, Li, Yanan, Xie, Qiongxuan, Dong, Yuqian, Mi, Ze, Ma, Xiaoqian, Rong, Pengfei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337087/
https://www.ncbi.nlm.nih.gov/pubmed/37438720
http://dx.doi.org/10.1186/s12967-023-04312-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337087/
https://www.ncbi.nlm.nih.gov/pubmed/37438720
http://dx.doi.org/10.1186/s12967-023-04312-2

Ejemplares similares